Evidence map›Paper›PMID 42738838›Full record

ArticleCells2026

Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model.

Anne R M Santos, Alessandra G Cruz, Felipe N Camargo, Jessica D M Santos, Jorge F A Model, José F T Silva, Sandro L Matos, Layanne C C Araujo, João Paulo Camporez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anne R M SantosDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0009-0007-8633-4595
Alessandra G CruzDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0002-6280-5969
Felipe N CamargoDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0003-3030-4817
Jessica D M SantosDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0002-7950-3617
Jorge F A ModelDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0003-3205-3011
José F T SilvaDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.
Sandro L MatosDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0002-4701-6769
Layanne C C AraujoSuperior Institute of Biomedical Sciences, Faculty of Education and Integrated Sciences, State University of Ceara, Fortaleza 60714-903, Brazil.ORCID 0000-0002-2988-4175
João Paulo CamporezDepartment of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.ORCID 0000-0003-3486-4301

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 313752/2023-0Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/06553-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/03604-9
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by hepatic steatosis, inflammation, fibrosis, and metabolic dysfunction, with limited therapeutic options currently available. This study investigated whether pharmacological inhibition of Galectin-3 (Gal-3), a β-galactoside-binding lectin implicated in inflammation and fibrosis, using modified citrus pectin (MCP), attenuates established MASH in ApoE-deficient mice. Mice were assigned to four groups: standard chow (CTL), standard chow plus MCP (CTL + MCP), Western diet with fructose-enriched drinking water (WD), and WD plus MCP (WD + MCP). MCP (1% in drinking water) was administered during the final four weeks of the 11-week experimental protocol, after the establishment of metabolic dysfunction and hepatic steatosis. Compared with untreated WD mice, WD + MCP mice exhibited improved glucose tolerance, as evidenced by a 22.9% reduction in glucose area under the curve (

Indexed as

Fatty LiverGalectin 3PectinsAnimalsDisease Models, AnimalLiverMaleMiceMice, Inbred C57BLSignal Transductioncitrus pectinGalectin 3PectinsGalectin-3hepatic insulin resistancehepatic steatosisinflammationliver fibrosismetabolic dysfunction-associated steatohepatitismodified citrus pectin

Identifiers

PMID42738838
PMCPMC13564570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.